Viekira on blockbuster pace as AbbVie adds 2nd HCV drug
This article was originally published in Scrip
Executive Summary
Viekira Pak, AbbVie's fixed-dose combination therapy for hepatitis C, fell short of Wall Street consensus sales estimates during the second quarter, but the Chicago-area pharma company pointed to several factors causing below-expectation US sales, while international sales exceeded projections.